Parametrica Management Ltd Sells 2,330 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Parametrica Management Ltd lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 59.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,613 shares of the biopharmaceutical company’s stock after selling 2,330 shares during the period. Regeneron Pharmaceuticals accounts for approximately 2.3% of Parametrica Management Ltd’s holdings, making the stock its 14th biggest position. Parametrica Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $1,417,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. FMR LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after acquiring an additional 669,517 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after acquiring an additional 34,326 shares during the last quarter. Morgan Stanley raised its position in Regeneron Pharmaceuticals by 2.7% in the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock worth $799,061,000 after purchasing an additional 25,792 shares during the period. Bank of New York Mellon Corp raised its position in Regeneron Pharmaceuticals by 0.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 967,414 shares of the biopharmaceutical company’s stock worth $796,142,000 after purchasing an additional 2,666 shares during the period. Finally, American Century Companies Inc. raised its position in Regeneron Pharmaceuticals by 3.4% in the 3rd quarter. American Century Companies Inc. now owns 916,718 shares of the biopharmaceutical company’s stock worth $754,422,000 after purchasing an additional 30,050 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.8 %

REGN traded down $7.48 during trading on Friday, hitting $883.20. The stock had a trading volume of 505,652 shares, compared to its average volume of 431,865. The company has a market capitalization of $96.94 billion, a PE ratio of 25.42, a PEG ratio of 2.56 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock has a 50 day simple moving average of $948.00 and a two-hundred day simple moving average of $893.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals’s revenue was up .6% compared to the same quarter last year. During the same period last year, the firm earned $10.96 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at $1,325,338. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The disclosure for this sale can be found here. Insiders sold a total of 11,022 shares of company stock worth $10,552,991 over the last three months. Corporate insiders own 8.83% of the company’s stock.

Analysts Set New Price Targets

REGN has been the topic of a number of recent analyst reports. Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective on the stock. TD Cowen increased their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Wednesday. UBS Group increased their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, April 15th. Finally, Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $977.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.